COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab after Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features

Protocol No
ECOG-EA3191
Principal Investigator
Aditya Shreenivas
Phase
II
Summary
This study is being done to answer the following question: Can we increase the length of time that you live by adding an immunotherapy drug called pembrolizumab to radiation or using pembrolizumab by itself after your surgery compared to one of the usual approaches with chemotherapy and radiation? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your HNSCC. The usual approach is defined as care most people get for HNSCC.
Description
Adjuvant Therapy with Pembrolizumab after Resection of Recurrent/Second Primary HNSCC
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Sub Category